Insulin Resistance Intervention After Stroke (IRIS) Trial
The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.
Stanford is now accepting new patients for this trial.
- Chitra Venkatasubramanian, MBBS, MD
- Neil Schwartz, MD, PhD
- Anna Finley Caulfield, MD
- Gregory W. Albers, MD
- Maarten Lansberg, MD, PhD
- drug : placebo
- drug : pioglitazone
Phase: Phase 3
Ages Eligible For Study: